Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Upcoming events – Reneuron’s conference data and Provention takes on Crohn’s
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
Where now for Oxurion?
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Upcoming events – catalysts approach for Catalyst and Oxurion
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Lukewarm data for Second Sight
Second Sight’s second product might lead the company to second place in the market.
Aldeyra seeks to Alleviate worries with conjunctivitis win
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.